• LAST PRICE
    0.9736
  • TODAY'S CHANGE (%)
    Trending Down-0.0364 (-3.6040%)
  • Bid / Lots
    0.9200/ 20
  • Ask / Lots
    1.0400/ 2
  • Open / Previous Close
    1.0100 / 1.0100
  • Day Range
    Low 0.9200
    High 1.0464
  • 52 Week Range
    Low 0.7015
    High 18.3600
  • Volume
    23,874
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 1.01
TimeVolumeSXTP
09:32 ET2371.01
09:42 ET11000.985
09:50 ET2090.9202
09:53 ET1000.9851
10:09 ET14001.02
10:11 ET2501.0464
10:42 ET3100.99
10:51 ET25470.9799
11:02 ET15000.98
11:27 ET4000.93
11:34 ET3100.9765
11:38 ET10000.97
12:15 ET5000.92
12:48 ET1500.97
01:04 ET28000.96
01:56 ET4110.96
02:34 ET4570.945
02:43 ET1110.9875
03:57 ET91210.9736
04:00 ET1990.9736
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSXTP
60 Degrees Pharmaceuticals Inc
1.9M
1.0x
---
United StatesCYTO
Altamira Therapeutics Ltd
1.7M
0.6x
---
United StatesVCBD
Vitalibis Inc
26.8K
0.0x
---
United StatesSYMQY
SymBio Pharmaceuticals Ltd
71.7M
-2.0x
---
United StatesOMHE
Omni Health Inc
1.1K
0.0x
---
United StatesNXEN
Nexien Biopharma Inc
1.4M
-5.5x
---
As of 2024-11-13

Company Information

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

Contact Information

Headquarters
1025 Connecticut Avenue Nw, Suite 1000WASHINGTON, DC, United States 20036
Phone
202-327-5422
Fax
302-636-5454

Executives

President, Chief Executive Officer, Director
Geoffrey Dow
Chief Financial Officer
Tyrone Miller
Chief Medical Officer
Bryan Smith
Director Nominee
Cheryl Xu
Independent Director Nominee
Charles Allen

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.9M
Revenue (TTM)
$441.3K
Shares Outstanding
1.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$0.95
Book Value
$10.06
P/E Ratio
1.0x
Price/Sales (TTM)
4.3
Price/Cash Flow (TTM)
---
Operating Margin
-2,113.98%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.